Compare Inovio Pharmaceuticals Inc (INO) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs LyondellBasell Industries NV — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while LyondellBasell Industries NV trades at $63.16 (market cap $20.67B). The key difference: LyondellBasell Industries NV is far larger — about 263.1× Inovio Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LYB | |
|---|---|---|
Market Cap | $78.55M | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $82.38 |
52-Week Low | $0.66 | $42.28 |
Enterprise Value | $49.56M | $32.26B |
Dividend Yield | — | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
LyondellBasell Industries (LYB) trades at $62.65, up 5.13% today, reflecting positive momentum following a strong Q2 2026 earnings beat. The stock shows bullish technical signals with moving averages supporting an uptrend, while fundamentals reveal a mixed picture with declining revenue but improving quarterly EPS. Recent news highlights supply disruptions supporting margins and analyst upgrades after the earnings report.
The outlook is cautiously optimistic with a consensus price target of $70.56, suggesting upside potential. Key opportunities include operational leverage from cost cuts and favorable petrochemical supply dynamics, but risks persist from volatile commodity markets and negative net income margins. Institutional sentiment leans positive with recent stake increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
